

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 June 2023 (08.06.2023)



(10) International Publication Number
WO 2023/101608 A3

(51) International Patent Classification:

C12N 5/16 (2006.01) G01N 33/50 (2006.01)
C12N 15/00 (2006.01) A61P 35/02 (2006.01)
C12N 15/113 (2010.01)

(21) International Application Number:

PCT/SG2022/050872

(22) International Filing Date:

30 November 2022 (30.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202113390W 01 December 2021 (01.12.2021) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: **SINGHAL, Amit**; c/o Singapore Immunology Network, 8A, Immunos, Biomedical Grove, #03-06, Singapore 138648 (SG). **DILIP, Kumar**; c/o Singapore Immunology Network, 8A, Immunos, Biomedical Grove, #04-06, Singapore 138648 (SG).

(74) Agent: **DONALDSON & BURKINSHAW LLP**; 24 Raffles Place, #15-00 Clifford Centre, Singapore 048621 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: A METHOD OF TREATING ACUTE MYELOID LEUKEMIA

(57) Abstract: There is provided a genetically modified cell wherein at least one gene has been deleted from the cell and the gene is selected from the group consisting of p50, p52, p65, c-Rel, and RelB. Also disclosed are methods of identifying a target for treating acute myeloid leukemia (AML) in a subject, methods of treating acute myeloid leukemia (AML) in a subject in need thereof, comprising inhibiting the activity of an NF-KB pathway. Also provided is an ATP13A2 inhibiting agent for use in therapy or medicine, for use in treating AML, and in the manufacture of a medicament for treating AML.

WO 2023/101608 A3